Biotest AG
BIESF · OTC
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.03 | 1.25 | 0.13 | -0.44 |
| FCF Yield | 0.00% | 0.80% | -2.30% | 5.09% |
| EV / EBITDA | 0.00 | 134.55 | 451.54 | 48.95 |
| Quality | ||||
| ROIC | 0.00% | -3.05% | -0.43% | 1.13% |
| Gross Margin | 11.35% | 26.00% | 19.38% | 32.59% |
| Cash Conversion Ratio | – | – | 6.02 | -0.39 |
| Growth | ||||
| Revenue 3-Year CAGR | 7.08% | 12.06% | 11.87% | 15.21% |
| Free Cash Flow Growth | 0.00% | 137.61% | -140.07% | 603.45% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 41.56 | -11.23 | 16.01 |
| Interest Coverage | -1.90 | 18.00 | -0.77 | 2.56 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.31 | 0.25 | 0.22 |
| Cash Conversion Cycle | 0.00 | 323.02 | 340.78 | 343.23 |